Last updated: 2026-09-09 19:18:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
UroGen Pharma Ltd. (URGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $44.78, with a market capitalisation of $2.16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.86 to $50.81. This page covers its latest market performance, valuation, price trends and company information.
$2.16B | |
$43.75 | |
$69.57 | |
$3.42 | |
$43.82 | |
692.55K | |
816.88K | |
-- | |
$50.81 | |
$15.86 | |
-- | |
-- |
UroGen Pharma Ltd. (URGN) is currently trading at $44.78 as of 2026-09-09 19:17:00, up 2.20% ($0.97) from the previous close of $43.82
During today's regular trading session, URGN has traded between $3.42 and $69.57, with a trading volume of 692.55K shares. The current price is near the middle of today's range.
Over the past seven days, UroGen Pharma Ltd. (URGN) moved from $43.62 to $44.78, representing a gain of 2.66% ($1.16).
The stock traded between $42.00 and $47.12 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 681.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.7%
URGN is currently trading at $44.78, placing it 82.7% of the way from its 52-week low of $15.86 to its 52-week high of $50.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 291 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of UroGen Pharma Ltd. (URGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.